<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alaunos Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc</link>
<description>Latest news and press releases for Alaunos Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 26 May 2026 15:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alaunos-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c7ed78dffbe2df11ba9c.webp</url>
<title>Alaunos Therapeutics, Inc.</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc</link>
</image>
<item>
<title>Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-reports-broad-metabolic-improvements-with-aln1003-in-obese-mouse-studies</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-reports-broad-metabolic-improvements-with-aln1003-in-obese-mouse-studies</guid>
<pubDate>Tue, 26 May 2026 15:01:00 GMT</pubDate>
<description>ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese miceA non-confidential investor presentation summarizing the preclinical dataset is now available FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today reported an integrated preclinical readout for ALN1</description>
</item>
<item>
<title>Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-reports-preclinical-aln1003-data-showing-effects-on-insulin-resistance-related-biomarkers-and-liver-histology-in-diet-induced-obesity-models</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-reports-preclinical-aln1003-data-showing-effects-on-insulin-resistance-related-biomarkers-and-liver-histology-in-diet-induced-obesity-models</guid>
<pubDate>Mon, 18 May 2026 12:00:00 GMT</pubDate>
<description>Findings from non-GLP DIO mouse studies show effects on insulin-resistance-related biomarkers, adipose endocrine signaling, and qualitative liver histology findings consistent with lower hepatic steatosisFORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic candidate. Across selected</description>
</item>
<item>
<title>Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-positive-preclinical-proof-of-concept-data-for-aln1003-a-differentiated-non-hormonal-oral-treatment-for-obesity-and-related-metabolic-disorders</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-positive-preclinical-proof-of-concept-data-for-aln1003-a-differentiated-non-hormonal-oral-treatment-for-obesity-and-related-metabolic-disorders</guid>
<pubDate>Mon, 02 Mar 2026 11:30:00 GMT</pubDate>
<description>The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse modelALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated miceEfforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq:</description>
</item>
<item>
<title>Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-2-0-120000998</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-2-0-120000998</guid>
<pubDate>Mon, 23 Jun 2025 12:00:00 GMT</pubDate>
<description>HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “SPA”) for the purchase and sale of an aggregate of 610,399 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.36 per share (or pre-funded warrant in lieu thereof) in a registered direct offering (the “Offering”) on June 20, 2025 based on the 5-day average Nasdaq offi</description>
</item>
<item>
<title>PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/pmgc-capital-llc-a-subsidiary-of-pmgc-holdings-inc-nasdaq-elab-to-file-schedule-13d-reporting-509percent-stake-in-alaunos-therapeutics-inc-nasdaq-tcrt-1</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/pmgc-capital-llc-a-subsidiary-of-pmgc-holdings-inc-nasdaq-elab-to-file-schedule-13d-reporting-509percent-stake-in-alaunos-therapeutics-inc-nasdaq-tcrt-1</guid>
<pubDate>Wed, 14 May 2025 12:00:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (Nasdaq: TCRT). PMGC Capital has acquired 83,500 shares of Alaunos Therapeutics, representing approximately 5.09% of the company’s outstanding</description>
</item>
<item>
<title>Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-third-quarter-2023-financial-results-phase-1-clinical-data-and-continued-exploration-of-strategic-alternatives</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-third-quarter-2023-financial-results-phase-1-clinical-data-and-continued-exploration-of-strategic-alternatives</guid>
<pubDate>Tue, 14 Nov 2023 05:00:00 GMT</pubDate>
<description>TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy</description>
</item>
<item>
<title>Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-second-quarter-2023-financial-results-interim-clinical-data-and-exploration-of-strategic-alternatives</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-second-quarter-2023-financial-results-interim-clinical-data-and-exploration-of-strategic-alternatives</guid>
<pubDate>Mon, 14 Aug 2023 04:00:00 GMT</pubDate>
<description>TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was</description>
</item>
<item>
<title>Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-presentation-at-the-2nd-hawaii-global-summit-on-thoracic-malignancies</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-presentation-at-the-2nd-hawaii-global-summit-on-thoracic-malignancies</guid>
<pubDate>Thu, 29 Jun 2023 04:00:00 GMT</pubDate>
<description>HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell</description>
</item>
<item>
<title>Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-to-present-early-data-from-tcr-t-library-phase-12-trial-at-2023-american-society-of-clinical-oncology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-to-present-early-data-from-tcr-t-library-phase-12-trial-at-2023-american-society-of-clinical-oncology-annual-meeting</guid>
<pubDate>Thu, 25 May 2023 04:00:00 GMT</pubDate>
<description>TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across</description>
</item>
<item>
<title>Alaunos Therapeutics Reports First Quarter 2023 Financial Results</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-reports-first-quarter-2023-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-reports-first-quarter-2023-financial-results</guid>
<pubDate>Wed, 10 May 2023 04:00:00 GMT</pubDate>
<description>Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of</description>
</item>
<item>
<title>Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-to-report-first-quarter-2023-financial-results-on-may-10-2023</guid>
<pubDate>Wed, 03 May 2023 04:00:00 GMT</pubDate>
<description>HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy</description>
</item>
<item>
<title>Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-poster-presentation-at-the-american-society-of-clinical-oncology-asco-2023-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-poster-presentation-at-the-american-society-of-clinical-oncology-asco-2023-annual-meeting</guid>
<pubDate>Wed, 26 Apr 2023 04:00:00 GMT</pubDate>
<description>HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell</description>
</item>
<item>
<title>Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-appoints-dr-robert-j-hofmeister-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-appoints-dr-robert-j-hofmeister-to-board-of-directors</guid>
<pubDate>Thu, 30 Mar 2023 04:00:00 GMT</pubDate>
<description>Industry leader brings more than 25 years of scientific leadership and expertise in T-cell therapy development HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results</guid>
<pubDate>Tue, 07 Mar 2023 05:00:00 GMT</pubDate>
<description>Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvironment; provides</description>
</item>
<item>
<title>Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-pricing-of-public-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-pricing-of-public-offering-of-common-stock</guid>
<pubDate>Tue, 29 Nov 2022 05:00:00 GMT</pubDate>
<description>HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell</description>
</item>
<item>
<title>Alaunos Therapeutics Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-proposed-public-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-proposed-public-offering-of-common-stock</guid>
<pubDate>Mon, 28 Nov 2022 05:00:00 GMT</pubDate>
<description>HOUSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell</description>
</item>
<item>
<title>Alaunos Therapeutics Reports Third Quarter 2022 Financial Results</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-reports-third-quarter-2022-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-reports-third-quarter-2022-financial-results</guid>
<pubDate>Mon, 14 Nov 2022 05:00:00 GMT</pubDate>
<description>Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the</description>
</item>
<item>
<title>Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-to-report-third-quarter-2022-financial-results-on-november-14-2022</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-to-report-third-quarter-2022-financial-results-on-november-14-2022</guid>
<pubDate>Tue, 08 Nov 2022 05:00:00 GMT</pubDate>
<description>HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report</description>
</item>
<item>
<title>Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-highlights-data-from-tcr-t-library-phase-12-trial-at-the-cri-enci-aacr-sixth-international-cancer-immunotherapy-conference</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-highlights-data-from-tcr-t-library-phase-12-trial-at-the-cri-enci-aacr-sixth-international-cancer-immunotherapy-conference</guid>
<pubDate>Wed, 21 Sep 2022 04:00:00 GMT</pubDate>
<description>First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post infusionSleeping Beauty</description>
</item>
<item>
<title>Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy</title>
<link>https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-early-clinical-data-showing-objective-clinical-response-using-its-tcr-t-cell-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/alaunos-therapeutics-inc/news/alaunos-therapeutics-announces-early-clinical-data-showing-objective-clinical-response-using-its-tcr-t-cell-therapy</guid>
<pubDate>Tue, 06 Sep 2022 04:00:00 GMT</pubDate>
<description>First patient dosed achieved a confirmed objective partial response Second patient dosed at second dose level; cleared 28-day safety windowData to be</description>
</item>
</channel>
</rss>